PBM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Psyence Biomedical Ltd (PBM) is not a good buy for a beginner, long-term investor at this time. Despite the recent surge in pre-market price driven by positive news catalysts, the company's financial performance is extremely weak, with significant losses and no revenue growth. Additionally, technical indicators show the stock is overbought, suggesting a potential pullback. Without strong proprietary trading signals or evidence of sustained growth, this stock does not align with the user's investment strategy.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 96.662, signaling the stock is overbought. Moving averages are converging, and the pre-market price has surged significantly, suggesting a potential short-term peak. Key resistance levels are at R1: 8.01 and R2: 9.83, while support levels are at S1: 2.12 and S2: 0.3.
Positive news around ibogaine research and federal funding for PTSD and traumatic brain injuries has driven strong market confidence, with shares surging over 141%. Retail sentiment remains extremely bullish.
The stock has declined 95% over the past year, and financial performance is extremely weak, with significant losses and no revenue growth. Technical indicators suggest the stock is overbought, increasing the risk of a pullback.
In 2026/Q2, revenue remained at 0 with no growth. Net income dropped significantly to -753,254, down -632.44% YoY. EPS also declined to -3.18, down -142.23% YoY. Gross margin remained at 0 with no improvement.
No analyst rating or price target changes are available for this stock.
